SCHEMBL9511744

SCHEMBL9511744

CC(=O)c1ccc(O)c(-c2ccccc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
BACE1 P56817 2/20 0.54
PKM P14618 1/20 0.53
S100A4 P26447 1/20 0.51
SYK P43405 1/20 0.49
AURKB Q96GD4 1/20 0.49
INCENP Q9NQS7 1/20 0.49
EGFR P00533 1/20 0.47
ALDH1A1 P00352 5/20 0.47
HPGD P15428 4/20 0.47
BCL2L1 Q07817 1/20 0.47
HSD17B10 Q99714 1/20 0.47
LMNA P02545 1/20 0.46
KDM4E B2RXH2 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
HSD17B1 P14061 2/20 0.45
PELI1 Q96FA3 1/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL901046 0.85 BACE1 (0.58) MAPTSMN1; SMN2BACE1EGFRALDH1A1
SCHEMBL29772126 0.85 BACE1 (0.58) MAPTSMN1; SMN2BACE1EGFRALDH1A1
SCHEMBL8658097 0.85 BACE1 (0.58) MAPTSMN1; SMN2BACE1EGFRALDH1A1
SCHEMBL14176467 0.85 MAPT (0.61) MAPTSMN1; SMN2S100A4SYKAURKB
SCHEMBL10479736 0.83 BACE1 (0.56) MAPTSMN1; SMN2BACE1EGFRALDH1A1
SCHEMBL3221434 0.81 EGFR (0.58) MAPTBACE1EGFRALDH1A1HSD17B10
SCHEMBL11486731 0.81 BACE1 (0.54) MAPTSMN1; SMN2BACE1EGFRALDH1A1
SCHEMBL16428951 0.81 BACE1 (0.54) MAPTBACE1EGFRALDH1A1HPGD
Acetophenone SCHEMBL27691627 0.81 MAPT (0.57) MAPTSMN1; SMN2BACE1ALDH1A1HPGD
SCHEMBL18585396 0.81 MAPT (0.57) MAPTSMN1; SMN2BACE1S100A4SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4464696-A1 CHEMICALLY DEGRADABLE EPOXY COMPOUND, METHOD FOR PREPARING SAME, EPOXY COMPOSITE MATERIAL COMPRISING SAME, AND DECOMPOSITION METHOD THEREOF Konkuk University Industrial Cooperation Corp. (KR) 2024-11-20 EP claimed
US-20230365742-A1 CHEMICALLY DEGRADABLE EPOXY COMPOUND, METHOD OF PREPARING SAME COMPOUND, EPOXY COMPOSITE MATERIAL CONTAINING SAME COMPOUND, AND METHOD OF DEGRADING SAME COMPOSITE MATERIAL KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP (KR) 2023-11-16 US claimed
WO-2023136620-A1 CHEMICALLY DEGRADABLE EPOXY COMPOUND, METHOD FOR PREPARING SAME, EPOXY COMPOSITE MATERIAL COMPRISING SAME, AND DECOMPOSITION METHOD THEREOF 건국대학교 산학협력단 2023-07-20 WO claimed
EP-0337434-B1 Process for preparing diphenol monoesters substituted with aryl groups HIMONT ITALIA (IT) 1993-10-20 EP claimed
EP-4464696-A1 CHEMICALLY DEGRADABLE EPOXY COMPOUND, METHOD FOR PREPARING SAME, EPOXY COMPOSITE MATERIAL COMPRISING SAME, AND DECOMPOSITION METHOD THEREOF Konkuk University Industrial Cooperation Corp. (KR) 2024-11-20 EP disclosed
US-20230365742-A1 CHEMICALLY DEGRADABLE EPOXY COMPOUND, METHOD OF PREPARING SAME COMPOUND, EPOXY COMPOSITE MATERIAL CONTAINING SAME COMPOUND, AND METHOD OF DEGRADING SAME COMPOSITE MATERIAL KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP (KR) 2023-11-16 US disclosed
WO-2023136620-A1 CHEMICALLY DEGRADABLE EPOXY COMPOUND, METHOD FOR PREPARING SAME, EPOXY COMPOSITE MATERIAL COMPRISING SAME, AND DECOMPOSITION METHOD THEREOF 건국대학교 산학협력단 2023-07-20 WO disclosed
EP-1656345-B1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB CO (US) 2013-10-16 EP disclosed
US-7829571-B2 Cyclic derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2010-11-09 US disclosed
US-7829571-B2 Cyclic derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2010-11-09 US disclosed
US-20090124668-A1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2009-05-14 US disclosed
US-20090124668-A1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2009-05-14 US disclosed
US-7163937-B2 Cyclic derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-16 US disclosed
US-7163937-B2 Cyclic derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-16 US disclosed
EP-0337434-B1 Process for preparing diphenol monoesters substituted with aryl groups HIMONT ITALIA (IT) 1993-10-20 EP disclosed
EP-0190815-B1 PROCESS FOR PRODUCING AROMATIC DIOLS CELANESE CORPORATION (US) 1990-05-02 EP disclosed
EP-0337434-A2 Process for preparing diphenol monoesters substituted with aryl groups HIMONT ITALIA S.r.l. (IT) 1989-10-18 EP disclosed
EP-0178929-B1 PROCESS FOR PRODUCING AROMATIC DIOLS AND THEIR ESTER AND ETHER DERIVATIVES CELANESE CORPORATION (US) 1989-03-22 EP disclosed
EP-0190815-A2 Process for producing aromatic diols CELANESE CORPORATION (US) 1986-08-13 EP disclosed
EP-0178929-A1 Process for producing aromatic diols and their ester and ether derivatives CELANESE CORPORATION (US) 1986-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124668-A1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CCL11, CCL2, CCR1 MAPT 4523/4885SMN1; SMN2 3850/4885BACE1 2671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.